U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H9N2O3S.Na
Molecular Weight 236.223
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFACETAMIDE SODIUM ANHYDROUS

SMILES

[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1

InChI

InChIKey=PQMSFAORUFMASU-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;/h2-5H,9H2,1H3,(H,10,11);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C8H10N2O3S
Molecular Weight 214.242
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BLEPHAMIDE

Approved Use

Blephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

Launch Date

1961
Curative
KLARON

Approved Use

Klaron Lotion is indicated in the topical treatment of acne vulgaris.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
99.2 μg/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1803 μg × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.3 h
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13 h
single, ocular
SULFACETAMIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82%
single, ocular
SULFACETAMIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015-05-18
An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.
2010-12
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
2010-11
[Rosacea: pathogenesis, clinical forms and therapy].
2010-07-25
Synthesis of novel selenium-containing sulfa drugs and their antibacterial activities.
2010-07-21
Curvularia keratomycosis in a dog.
2010-03
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses.
2010-03
Pharmacokinetic study on the mechanism of interaction of sulfacetamide sodium with bovine serum albumin: a spectroscopic method.
2010-03
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
2010
Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties.
2010
A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection.
2009-10-23
Updates on the pathophysiology and management of acne rosacea.
2009-09
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.
2009-09
Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model.
2009-08
Analytical method for simultaneous determination of pesticide and veterinary drug residues in milk by CE-MS.
2009-05
Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam.
2009-03
Rosacea and its topical management.
2009-02
Expression profile of CREB knockdown in myeloid leukemia cells.
2008-09-18
Comparative study of robustness between micellar electrokinetic capillary chromatography and high-performance liquid chromatography using one-variable-at-a-time and a new multi-variable-at-a-time approach.
2008-07-14
Ocular myasis and associated mucopurulent conjuctivitis acquired occupationally: A case study.
2008-04
Optimal conditions for determination of zinc bacitracin, polymyxin B, oxytetracycline and sulfacetamide in animal feed by micellar electrokinetic capillary chromatography.
2008-04
Application of liquid-liquid-liquid microextraction and high-performance liquid-chromatography for the determination of sulfonamides in water.
2008-03-31
Emerging topical antimicrobial options for mild-to-moderate acne: a review of the clinical evidence.
2008-02
N-(2,6-Dimethyl-phen-yl)-2-methyl-acetamide.
2008-01-09
Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea.
2008
Researches concerning the synthesis and antituberculosis action of some new sulphacetamide derivatives.
2007-09-07
[Simultaneous determination of seven sulfonamides and metronidazole and chloramphenicol in cosmetics by high performance liquid chromatography].
2007-09
A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations.
2007-09
Pilot investigation of the hydrating effects of topical acne medications.
2007-08
Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection.
2007-03-22
Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.
2007-03
[Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography].
2007-03
Demodex folliculorum and Demodex brevis as a cause of chronic marginal blepharitis.
2007
Toxicity and biodegradability of sulfonamides and products of their photocatalytic degradation in aqueous solutions.
2006-11
Determination of sulfonamide antibiotics in wastewater: a comparison of solid phase microextraction and solid phase extraction methods.
2006-10-27
Combination topical therapy in the treatment of acne.
2006-08
Copper complexes with heterocyclic sulfonamides: synthesis, spectroscopic characterization, microbiological and SOD-like activities: crystal structure of [Cu(sulfisoxazole)2(H2O)4] . 2H2O.
2006-07
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
2006-04
Broad-specificity immunoassays for sulfonamide detection: immunochemical strategy for generic antibodies and competitors.
2006-03-01
Simultaneous determination of 16 sulfonamides in honey by liquid chromatography/tandem mass spectrometry.
2006-01-03
Topical therapies for rosacea.
2006-01
Monitoring of five sulfonamide antibacterial residues in milk by in-tube solid-phase microextraction coupled to high-performance liquid chromatography.
2005-11-02
Resistant scalp folliculitis secondary to Demodex infestation.
2005-11
Demodex mites as a cause of human disease.
2005-11
Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia.
2005-09-30
Topical metronidazole combination therapy in the clinical management of rosacea.
2005-07-12
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea.
2005-06
Multiresidue determination of sulfonamides in a variety of biological matrices by supported liquid membrane with high pressure liquid chromatography-electrospray mass spectrometry detection.
2004-09-08
Acute infectious conjunctivitis in childhood.
2001-07
Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.
1990-02
Patents

Sample Use Guides

Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration: Other
In Vitro Use Guide
P. aeruginosa, S. marcescens, St. epidermidis, C. albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:19:56 GMT 2025
Edited
by admin
on Mon Mar 31 21:19:56 GMT 2025
Record UNII
30760ZE777
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETAMIDE, N-((4-AMINOPHENYL)SULFONYL)-, MONOSODIUM SALT
Preferred Name English
SULFACETAMIDE SODIUM ANHYDROUS
Common Name English
SULPHACETAMIDE SODIUM
Common Name English
SODIUM SULFACETAMIDE, ANHYDROUS
Common Name English
SULFACETAMIDE SODIUM SALT [MI]
Common Name English
Sulfacetamide sodium [WHO-DD]
Common Name English
N-SULFANILYLACETAMIDE MONOSODIUM SALT
Common Name English
Code System Code Type Description
EVMPD
SUB20814
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
CHEBI
9327
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
PUBCHEM
4022878
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-848-4
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
CAS
127-56-0
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
CHEBI
63858
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID40889336
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
MERCK INDEX
m10301
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY Merck Index
FDA UNII
30760ZE777
Created by admin on Mon Mar 31 21:19:56 GMT 2025 , Edited by admin on Mon Mar 31 21:19:56 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY